Logotipo del repositorio
Logotipo del repositorio
 

Cellular mechanisms triggered by the cotreatment of resveratrol and doxorubicin in breast cancer: A translational in vitro–In silico model

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2spa
dc.contributor.authorVargas, José Eduardo
dc.contributor.authorPuga, Renato
dc.contributor.authorLenz, Guido
dc.contributor.authorTrindade, Cristiano
dc.contributor.authorFilippi-Chiela, Eduardo
dc.date.accessioned2020-11-05T17:55:44Z
dc.date.available2020-11-05T17:55:44Z
dc.date.issued2020
dc.description.abstractDoxorubicin (Doxo) is the most effective chemotherapeutic agent for the treatment of breast cancer. However, resistance to Doxo is common. Adjuvant compounds capable of modulating mechanisms involved in Doxo resistance may potentiate the effectiveness of the drug. Resveratrol (Rsv) has been tested as an adjuvant in mammary malignancies. However, the cellular and molecular mechanisms underlying the effects of cotreatment with Doxo and Rsv in breast cancer are poorly understood. Here, we combined in vitro and in silico analysis to characterize these mechanisms. In vitro, we employed a clinically relevant experimental design consisting of acute (24 h) treatment followed by 15 days of analysis. Acute Rsv potentiated the long-lasting effect of Doxo through the induction of apoptosis and senescence. Cells that survived to the cotreatment triggered high levels of autophagy. Autophagy inhibition during its peak of activation but not concomitant with Doxo+Rsv increased the long-term toxicity of the cotreatment. To uncover key proteins potentially associated with in vitro effects, an in silico multistep strategy was implemented. Chemical-protein networks were predicted based on constitutive gene expression of MCF7 cells and interatomic data from breast cancer. Topological analysis, KM survival analysis, and a quantitative model based on the connectivity between apoptosis, senescence, and autophagy were performed. We found seven putative genes predicted to be modulated by Rsv in the context of Doxo treatment: CCND1, CDH1, ESR1, HSP90AA1, MAPK3, PTPN11, and RPS6KB1. Six out of these seven genes have been experimentally proven to be modulated by Rsv in cancer cells, with 4 of the 6 genes in MCF7 cells. In conclusion, acute Rsv potentiated the long-term toxicity of Doxo in breast cancer potentially through the modulation of genes and mechanisms involved in Doxo resistance. Rational autophagy inhibition potentiated the effects of Rsv+Doxo, a strategy that should be further tested in animal models.eng
dc.format.mimetypepdfeng
dc.identifier.doihttps://doi.org/10.1155/2020/5432651
dc.identifier.issn19420994
dc.identifier.urihttps://hdl.handle.net/20.500.12442/6761
dc.identifier.urlhttps://www.hindawi.com/journals/omcl/2020/5432651/
dc.language.isoengeng
dc.publisherHindawieng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceOxidative Medicine and Cellular Longevityeng
dc.titleCellular mechanisms triggered by the cotreatment of resveratrol and doxorubicin in breast cancer: A translational in vitro–In silico modeleng
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicoeng
dcterms.referencesL. A. Torre, F. Islami, R. L. Siegel, E. M. Ward, and A. Jemal, “Global cancer in women: burden and trends,” Cancer Epidemiology, Biomarkers & Prevention, vol. 26, no. 4, pp. 444– 457, 2017.eng
dcterms.referencesO. Abe, R. Abe, K. Enomoto, K. Kikuchi, H. Koyama et al., “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” Lancet, vol. 365, no. 9472, pp. 1687–1717, 2005.eng
dcterms.referencesN. Howlader, S. F. Altekruse, C. I. Li et al., “US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status,” JNCI: Journal of the National Cancer Institute, vol. 106, no. 5, 2014.eng
dcterms.referencesN. Howlader, K. A. Cronin, A. W. Kurian, and R. Andridge, “Differences in breast cancer survival by molecular subtypes in the United States,” Cancer Epidemiology, Biomarkers & Prevention, vol. 27, no. 6, pp. 619–626, 2018.eng
dcterms.referencesM. Videira, R. L. Reis, and M. A. Brito, “Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance,” Biochim. Biophys. Acta - Rev. Cancer., vol. 1846, no. 2, pp. 312–325, 2014.eng
dcterms.referencesThe Cancer Genome Atlas Network, “Comprehensive molecular portraits of human breast tumours,” Nature, vol. 490, no. 7418, pp. 61–70, 2012.eng
dcterms.referencesK. Kalecky, R. Modisette, S. Pena, Y. R. Cho, and J. Taube, “Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes,” BMC Cancer, vol. 20, no. 1, 2020.eng
dcterms.referencesJ. A. Mestres, A. B. iMolins, L. C. Martínez et al., “Defining the optimal sequence for the systemic treatment of metastatic breast cancer,” Clinical and Translational Oncology, vol. 19, no. 2, pp. 149–161, 2017.eng
dcterms.referencesG. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004.eng
dcterms.referencesL. Smith, M. B. Watson, S. L. O'Kane, P. J. Drew, M. J. Lind, and L. Cawkwell, “The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays,” Molecular Cancer Therapeutics, vol. 5, no. 8, pp. 2115–2120, 2006.eng
dcterms.referencesX. Jin, Y. Wei, Y. Liu et al., “Resveratrol promotes sensitization to doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/β-catenin signaling pathway in breast cancer,” Cancer Medicine, vol. 8, no. 3, pp. 1246–1257, 2019.eng
dcterms.referencesT. H. Kim, Y. J. Shin, A. J. Won et al., “Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin,” Biochim. Biophys. Acta - Gen. Subj., vol. 1840, no. 1, pp. 615–625, 2014.eng
dcterms.referencesY. Zhao, M. L. Huan, M. Liu et al., “Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance,” Scientific Reports, vol. 6, no. 1, pp. 1–15, 2016.eng
dcterms.referencesD. Sinha, N. Sarkar, J. Biswas, and A. Bishayee, “Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms,” Seminars in Cancer Biology, vol. 40-41, pp. 209–232, 2016.eng
dcterms.referencesP. A. Volkart, R. B. Gassen, B. M. Nogueira, B. N. Porto, J. E. Vargas, and A. A. Souto, “Antitumor activity of resveratrol is independent of Cu(II) complex formation in MCF-7 cell line,” Bioorganic & Medicinal Chemistry Letters, vol. 27, no. 15, pp. 3238–3242, 2017.eng
dcterms.referencesA. Chimento, R. Sirianni, C. Saturnino, A. Caruso, M. Stefania Sinicropi, and V. Pezzi, “Resveratrol and Its Analogs As Antitumoral Agents For Breast Cancer Treatment,” Mini-Reviews in Medicinal Chemistry, vol. 16, no. 9, pp. 699–709, 2016.eng
dcterms.referencesB. S. Vinod, H. H. Nair, V. Vijayakurup et al., “Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxelmediated activation of HER-2–Akt axis,” Cell Death Discov., vol. 1, no. 1, pp. 1–9, 2015.eng
dcterms.referencesM. Fukui, N. Yamabe, and B. T. Zhu, “Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo,” European Journal of Cancer, vol. 46, no. 10, pp. 1882–1891, 2010.eng
dcterms.referencesS. E. Al-Harthi, O. M. Alarabi, W. S. Ramadan et al., “Amelioration of doxorubicin-induced cardiotoxicity by resveratrol,” Molecular Medicine Reports, vol. 10, no. 3, pp. 1455–1460, 2014.eng
dcterms.referencesE. Tatlidede, O. Sehirli, A. Velioğlu-Oğünc et al., “Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage,” Free Radical Research, vol. 43, no. 3, pp. 195–205, 2009.eng
dcterms.referencesW. Zhu, W. Qin, K. Zhang et al., “Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer,” Nutrition and Cancer, vol. 64, no. 3, pp. 393–400, 2012.eng
dcterms.referencesW. Strober, “Trypan Blue Exclusion Test of Cell Viability,” Current Protocols in Immunology, vol. 111, no. 1, pp. - A3.B.1–A3.B.3, 2015.eng
dcterms.referencesA. O. Silva, E. Dalsin, G. R. Onzi, E. C. Filippi-Chiela, and G. Lenz, “The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines,” Experimental Cell Research, vol. 348, no. 2, pp. 177–183, 2016.eng
dcterms.referencesM. P. Thomé, E. C. Filippi-Chiela, E. S. Villodre et al., “Ratiometric analysis of acridine orange staining in the study of acidic organelles and autophagy,” Journal of Cell Science, vol. 129, no. 24, pp. 4622–4632, 2016.eng
dcterms.referencesL. L. Zamin, E. C. Filippi-Chiela, P. Dillenburg-Pilla, F. Horn, C. Salbego, and G. Lenz, “Resveratrol and quercetin cooperate to induce senescence-like growth arrest in C6 rat glioma cells,” Cancer Science, vol. 100, no. 9, pp. 1655–1662, 2009.eng
dcterms.referencesE. C. Filippi-Chiela, M. M. Oliveira, B. Jurkovski, S. M. Callegari-Jacques, V. D. d. Silva, and G. Lenz, “Nuclear Morphometric Analysis (NMA): Screening of Senescence, Apoptosis and Nuclear Irregularities,” PLoS ONE, vol. 7, no. 8, p. e42522, 2012.eng
dcterms.referencesG. K. Smyth, “Limma: linear models for microarray dat,” in Bioinformatics and computational biology solutions using R and Bioconductor, pp. 397–420, Springer, New York, NY, 2005, http://link.springer.com/chapter/10.1007/0-387- 29362-0_23%5Cnpapers3://publication/uuid/7617F4B3- 24B5-4568-9C76-1C22000E7796.eng
dcterms.referencesN. T. Doncheva, J. H. Morris, J. Gorodkin, and L. J. Jensen, “Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data,” Journal of Proteome Research, vol. 18, no. 2, pp. 623–632, 2018.eng
dcterms.referencesP. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models,” Genome Research, vol. 13, p. 426, 1971.eng
dcterms.referencesS. Pletscher-Frankild, A. Pallejà, K. Tsafou, J. X. Binder, and L. J. Jensen, “DISEASES: text mining and data integration of disease-gene associations,” Methods, vol. 74, pp. 83–89, 2015.eng
dcterms.referencesD. Szklarczyk, A. Santos, C. Von Mering, L. J. Jensen, P. Bork, and M. Kuhn, “STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data,” Nucleic Acids Research, vol. 44, no. D1, pp. D380–D384, 2016.eng
dcterms.referencesY. Assenov, F. Ramírez, S.-E. Schelhorn, T. Lengauer, and M. Albrecht, “Computing topological parameters of biological networks,” Bioinformatics, vol. 24, no. 2, pp. 282–284, 2008.eng
dcterms.referencesM. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, and K. Morishima, “KEGG: new perspectives on genomes, pathways, diseases and drugs,” Nucleic Acids Research, vol. 45, no. D1, pp. D353–D361, 2017.eng
dcterms.referencesG. Scardoni, M. Petterlini, and C. Laudanna, “Analyzing biological network parameters with CentiScaPe,” Bioinformatics, vol. 25, no. 21, pp. 2857–2859, 2009.eng
dcterms.referencesM. E. J. Newman, “A measure of betweenness centrality based on random walks,” Social Networks, vol. 27, no. 1, pp. 39–54, 2005.eng
dcterms.referencesJ. E. Vargas, R. Puga, J. d. F. Poloni et al., “A Network Flow Approach to Predict Protein Targets and Flavonoid Backbones to Treat Respiratory Syncytial Virus Infection,” BioMed Research International, vol. 2015, Article ID 301635, 9 pages, 2015.eng
dcterms.referencesG. Bindea, B. Mlecnik, H. Hackl et al., “ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks,” Bioinformatics, vol. 25, no. 8, pp. 1091–1093, 2009.eng
dcterms.referencesD. S. Chandrashekar, B. Bashel, S. A. H. Balasubramanya et al., “UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses,” Neoplasia, vol. 19, no. 8, pp. 649–658, 2017.eng
dcterms.referencesB. Györffy, A. Lanczky, A. C. Eklund et al., “An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients,” Breast Cancer Research and Treatment, vol. 123, no. 3, pp. 725–731, 2010.eng
dcterms.referencesY. Han, S. Fan, T. Qin et al., “Role of autophagy in breast cancer and breast cancer stem cells (review),” International Journal of Oncology, vol. 52, pp. 1057–1070, 2018.eng
dcterms.referencesJ. I. G. Solari, E. Filippi-Chiela, E. S. Pilar et al., “Damageassociated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells,” BMC Cancer, vol. 20, no. 1, 2020.eng
dcterms.referencesM. Szostakowska, A. Trębińska-Stryjewska, E. A. Grzybowska, and A. Fabisiewicz, “Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals,” Breast Cancer Research and Treatment, vol. 173, no. 3, pp. 489–497, 2019.eng
dcterms.referencesC. Chen, L. Lu, S. Yan et al., “Autophagy and doxorubicin resistance in cancer,” Anti-Cancer Drugs, vol. 29, no. 1, pp. 1–9, 2018.eng
dcterms.referencesN. Matsumura, B. N. Zordoky, I. M. Robertson, and S. M. Hamza, “Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes,” Cardiovascular Research, vol. 114, no. 10, 2017.eng
dcterms.referencesY. Fu, H. Chang, X. Peng et al., “Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/β-catenin signaling pathway,” PLoS One, vol. 9, no. 7, pp. e102535–e102538, 2014.eng
dcterms.referencesY. N. Zhao, Y. N. Cao, J. Sun et al., “Anti-breast cancer activity of resveratrol encapsulated in liposomes,” Journal of Materials Chemistry B, vol. 8, no. 1, pp. 27–37, 2020.eng
dcterms.referencesY.-A. Kim, B. Choi, Y. Lee et al., “Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells,” Oncology Reports, vol. 11, pp. 441–446, 2004.eng
dcterms.referencesE. Pozo-Guisado, J. M. Merino, S. Mulero-Navarro et al., “Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-?B,” International Journal of Cancer, vol. 115, no. 1, pp. 74–84, 2005.eng
dcterms.referencesR. Venkatadri, T. Muni, A. K. V. Iyer, J. S. Yakisich, and N. Azad, “Role of apoptosis-related miRNAs in resveratrolinduced breast cancer cell death,” Cell Death & Disease, vol. 7, no. 2, p. e2104, 2016.eng
dcterms.referencesE. Pozo-Guisado, A. Alvarez-Barrientos, S. Mulero-Navarro, B. Santiago-Josefat, and P. M. Fernandez-Salguero, “The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle,” Biochemical Pharmacology, vol. 64, no. 9, pp. 1375–1386, 2002.eng
dcterms.referencesJ. Suh, D. H. Kim, and Y. J. Surh, “Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk,” Archives of Biochemistry and Biophysics, vol. 643, pp. 62–71, 2018.eng
dcterms.referencesD. Park, H. Jeong, M. N. Lee et al., “Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition,” Scientific Reports, vol. 6, no. 1, pp. 1–11, 2016.eng
dcterms.referencesJ. H. Ko, G. Sethi, J. Y. Um et al., “The role of resveratrol in cancer therapy,” International Journal of Molecular Sciences, vol. 18, no. 12, p. 2589, 2017.eng
dcterms.referencesY. Umekita, Y. Ohi, Y. Sagara, and H. Yoshida, “Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients,” International Journal of Cancer, vol. 98, no. 3, pp. 415–418, 2002.eng
dcterms.referencesN. Sausgruber, M. M. Coissieux, A. Britschgi et al., “Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases,” Oncogene, vol. 34, no. 17, pp. 2272–2278, 2015eng
dcterms.referencesJ. A. van der Hage, L. J. C. M. van den Broek, C. Legrand et al., “Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients,” British Journal of Cancer, vol. 90, no. 8, pp. 1543–1550, 2004.eng
dcterms.referencesL. Yang, X.‑. W. Wang, L.‑. P. Zhu et al., “Significance and prognosis of epithelial-cadherin expression in invasive breast carcinoma,” Oncology Letters, vol. 16, pp. 1659–1665, 2018.eng
dcterms.referencesS. Yu, M. Zhang, L. Huang et al., “ERK1 indicates good prognosis and inhibits breast cancer progression by suppressing YAP1 signaling,” Aging (Albany NY), vol. 11, no. 24, pp. 12295–12314, 2019.eng
dcterms.referencesE. Mechetner, A. Kyshtoobayeva, S. Zonis et al., “Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin,” Clinical Cancer Research, vol. 4, no. 2, pp. 389–398, 1998.eng
dcterms.referencesX. J. Fang, H. Jiang, Y. Q. Zhu, L. Y. Zhang, Q. H. Fan, and Y. Tian, “Doxorubicin induces drug resistance and expression of the novel CD44st via NF-κB in human breast cancerMCF-7 cells,” Oncology Reports, vol. 31, no. 6, pp. 2735–2742, 2014.eng
dcterms.referencesP. C. Marinello, C. Panis, T. N. X. Silva et al., “Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes,” Scientific Reports, vol. 9, no. 1, 2019.eng
dcterms.referencesJ. Huang, H. Li, and G. Ren, “Epithelial-mesenchymal transition and drug resistance in breast cancer (review),” International Journal of Oncology, vol. 47, no. 3, pp. 840–848, 2015.eng
dcterms.referencesL. Ponnusamy, P. K. S. Mahalingaiah, and K. P. Singh, “Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells,” European Journal of Pharmaceutical Sciences, vol. 104, pp. 424–433, 2017.eng
dcterms.referencesS. Chen, H. Wang, Z. Li et al., “Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription,” British Journal of Cancer, vol. 119, no. 2, pp. 182–192, 2018.eng
dcterms.referencesS. AbuHammad and M. Zihlif, “Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line,” Genomics, vol. 101, no. 4, pp. 213–220, 2013.eng
dcterms.referencesF. Ashour, M. H. Awwad, H. E. L. Sharawy, and M. Kamal, “Estrogen receptor positive breast tumors resist chemotherapy by the overexpression of P53 in cancer stem cells,” Journal of the Egyptian National Cancer Institute, vol. 30, no. 2, pp. 45–48, 2018.eng
dcterms.referencesB. D. Gehm, J. M. McAndrews, P. Y. Chien, and J. L. Jameson, “Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 25, pp. 14138–14143, 1997.eng
dcterms.referencesJ. Saluzzo, K. M. Hallman, K. Aleck et al., “The regulation of tumor suppressor protein, p53, and estrogen receptor (ERα) by resveratrol in breast cancer cells,” Genes and Cancer., vol. 7, no. 11-12, pp. 414–425, 2016.eng
dcterms.referencesE. M. Ciruelos Gil, “Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer,” Cancer Treatment Reviews, vol. 40, no. 7, pp. 862–871, 2014.eng
dcterms.referencesK. A. West, S. S. Castillo, and P. A. Dennis, “Activation of the PI3K/Akt pathway and chemotherapeutic resistance,” Drug Resistance Updates, vol. 5, no. 6, pp. 234–248, 2002.eng
dcterms.referencesY. Li, J. Liu, X. Liu et al., “Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9,” Applied Biochemistry and Biotechnology, vol. 135, no. 3, pp. 181–192, 2006.eng
dcterms.referencesA. M. Gao, Z. P. Ke, J. N. Wang, J. Y. Yang, S. Y. Chen, and H. Chen, “Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway,” Carcinogenesis, vol. 34, no. 8, pp. 1806–1814, 2013.eng
dcterms.referencesR. L. Yamnik, A. Digilova, D. C. Davis, Z. N. Brodt, C. J. Murphy, and M. K. Holz, “S6 kinase 1 regulates estrogen receptor α in control of breast cancer cell proliferation,” The Journal of Biological Chemistry, vol. 284, no. 10, pp. 6361– 6369, 2009.eng
dcterms.referencesY. B. Khotskaya, A. Goverdhan, J. Shen et al., “S6k1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer,” American Journal of Translational Research, vol. 6, no. 4, pp. 361–376, 2014.eng
dcterms.referencesD. M. Maruani, T. N. Spiegel, E. N. Harris et al., “Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation,” Oncogene, vol. 31, no. 49, pp. 5073–5080, 2012.eng
dcterms.referencesA. Alayev, P. F. Doubleday, S. M. Berger, B. A. Ballif, and M. K. Holz, “Phosphoproteomics reveals resveratroldependent inhibition of Akt/mTORC1/S6K1 signaling,” Journal of Proteome Research, vol. 13, no. 12, pp. 5734– 5742, 2014.eng
dcterms.referencesJ. S. Shin, S. H. Woo, and H. C. Lee, “Low doses of ionizing radiation suppress doxorubicin-induced senescence-like phenotypes by activation of ERK1/2 and suppression of p38 kinase in MCF7 human breast cancer cells,” International Journal of Oncology, vol. 36, no. 6, pp. 1445–1452, 2010.eng
dcterms.referencesC. Ahlin, C. Lundgren, E. Embretsén-Varro, K. Jirström, C. Blomqvist, and M. -L. Fjällskog, “High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ERnegative breast cancers,” Breast Cancer Research and Treatment, vol. 164, no. 3, pp. 667–678, 2017.eng
dcterms.referencesM. Stendahl, À. Kronblad, L. Rydén, S. Emdin, N. O. Bengtsson, and G. Landberg, “Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients,” British Journal of Cancer, vol. 90, no. 10, pp. 1942–1948, 2004.eng
dcterms.referencesN. V. Rusetskaya, N. Y. Lukyanova, and V. F. Chekhun, “Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin,” Experimental Oncology, vol. 31, no. 3, pp. 140–143, 2009.eng
dcterms.referencesA. Mondal and L. L. Bennett, “Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage,” Biomedicine & Pharmacotherapy, vol. 84, pp. 1906–1914, 2016.eng
dcterms.referencesR. Medina-Aguilar, L. A. Marchat, E. A. Ocampo et al., “Resveratrol inhibits cell cycle progression by targeting aurora kinase A and polo-like kinase 1 in breast cancer cells,” Oncology Reports, vol. 35, no. 6, pp. 3696–3704, 2016.eng
dcterms.referencesD. Luo, D. J. Liao, and Y. Sun, “CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDAMB231 cells,” Journal of Carcinogenesis, vol. 11, no. 1, p. 12, 2012.eng
dcterms.referencesZ.-P. Ji, L. Qiang, and J.-L. Zhang, “Transcription activated p73-modulated cyclin D1 expression leads to doxorubicin resistance in gastric cancer,” Experimental and Therapeutic Medicine, vol. 15, pp. 1831–1833, 2017.eng
dcterms.referencesF. Xu, F. Wang, T. Yang, Y. Sheng, T. Zhong, and Y. Chen, “Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells,” Cancer Cell International, vol. 14, no. 1, 2014.eng
dcterms.referencesG. Solanas, M. Porta-de-la-Riva, C. Agusti et al., “E-cadherin controls -catenin and NF- B transcriptional activity in mesenchymal gene expression,” Journal of Cell Science, vol. 121, no. 13, pp. 2224–2234, 2008.eng
dcterms.referencesZ. Hu, H. Fang, X. Wang, D. Chen, Z. Chen, and S. Wang, “Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma,” Oncology Reports, vol. 32, no. 1, pp. 205–212, 2014.eng
dcterms.referencesL. Lan, J. D. Holland, J. Qi et al., “Shp2 signaling suppresses senescence in PyMT‐induced mammary gland cancer in mice,” The EMBO Journal, vol. 34, no. 18, pp. 2383–2383, 2015.eng
dcterms.referencesD. A. Jerjees, M. Alabdullah, M. Alkaabi et al., “ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer,” Breast Cancer Research and Treatment, vol. 147, no. 1, pp. 25–37, 2014.eng
dcterms.referencesJ. Xu, D. Liu, H. Niu et al., “Resveratrol reverses doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer,” Journal of Experimental & Clinical Cancer Research, vol. 36, no. 1, 2017.eng
dcterms.referencesG. Rai, S. Suman, S. Mishra, and Y. Shukla, “Evaluation of growth inhibitory response of resveratrol and salinomycin combinations against triple negative breast cancer cells,” Biomedicine & Pharmacotherapy, vol. 89, pp. 1142–1151, 2017.eng
dcterms.referencesI. C. Iser, S. M. Ceschini, G. R. Onzi, A. P. S. Bertoni, G. Lenz, and M. R. Wink, “Conditioned medium from adiposederived stem cells (ADSCs) promotes epithelial-to-mesenchymal- like transition (EMT-like) in glioma cells in vitro,” Molecular Neurobiology, vol. 53, no. 10, pp. 7184–7199, 2016.eng
dcterms.referencesX. D. Zhou and Y. M. Agazie, “Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells,” Cell Death and Differentiation, vol. 15, no. 6, pp. 988–996, 2008.eng
dcterms.referencesY. Sun, Q. M. Zhou, Y. Y. Lu et al., “Resveratrol inhibits the migration and metastasis ofMDA-MB-231 human breast cancer by reversing TGF-β1-induced epithelial-mesenchymal transition,” Molecules, vol. 24, no. 6, p. 1131, 2019.eng
dcterms.referencesV. Padmanaban, I. Krol, Y. Suhail et al., “E-cadherin is required for metastasis in multiple models of breast cancer,” Nature, vol. 573, no. 7774, pp. 439–444, 2019.eng
dcterms.referencesM. Lu, S. Marsters, X. Ye, E. Luis, L. Gonzalez, and A. Ashkenazi, “E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis,” Molecular Cell, vol. 54, no. 6, pp. 987–998, 2014.eng
dcterms.referencesL. Wang, Z. Li, C. Wang et al., “E-cadherin decreased human breast cancer cells sensitivity to staurosporine by upregulating Bcl-2 expression,” Archives of Biochemistry and Biophysics, vol. 481, no. 1, pp. 116–122, 2009.eng
dcterms.referencesJ. Liu, X. Sun, S. Qin et al., “CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer,” Oncology Letters, vol. 11, no. 4, pp. 2635–2643, 2016.eng
dcterms.referencesT. Han, S. Jiang, H. Zheng et al., “Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis,” Nature Communications, vol. 10, no. 1, p. 3716, 2019.eng
dcterms.referencesN. Matsuyoshi, S. Hirano, M. Takeichi, H. Tahara, T. Kobayashi, and T. Mori, “Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis,” Cancer Research, vol. 53, pp. 1696–1701, 1993.eng
dcterms.referencesY. Zhou, Y. Hu, M. Yang et al., “The miR-106b∼25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the Ecadherin transcriptional activator EP300,” Cell Death and Differentiation, vol. 21, no. 3, pp. 462–474, 2014.eng
dcterms.referencesD. Vergara, C. M. Valente, A. Tinelli et al., “Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells,” Cancer Letters, vol. 310, no. 1, pp. 1–8, 2011.eng
dcterms.referencesE. Tili, J. J. Michaille, H. Alder et al., “Resveratrol modulates the levels of microRNAs targeting genes encoding tumorsuppressors and effectors of TGFβ signaling pathway in SW480 cells,” Biochemical Pharmacology, vol. 80, no. 12, pp. 2057–2065, 2010.eng
dcterms.referencesX. Zhou, J. Coad, B. Ducatman, and Y. M. Agazie, “SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis,” Histopathology, vol. 53, no. 4, pp. 389–402, 2008.eng
dcterms.referencesN. Aceto, N. Sausgruber, H. Brinkhaus et al., “Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop,” Nature Medicine, vol. 18, no. 4, pp. 529–537, 2012.eng
dcterms.referencesX. Zhou and Y. M. Agazie, “Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation,” The Journal of Biological Chemistry, vol. 284, no. 18, pp. 12226–12234, 2009.eng
dcterms.referencesL. Zhang, X. Wen, M. Li, S. Li, and H. Zhao, “Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene,” BioFactors, vol. 44, no. 1, pp. 61–68, 2018.eng
dcterms.referencesG. Bousquet, M. E. Bouchtaoui, T. Sophie et al., “Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer,” Oncotarget, vol. 8, no. 21, pp. 35205–35221, 2017.eng
dcterms.referencesN. E. Bhola, V. M. Jansen, J. P. Koch et al., “Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population,” Cancer Research, vol. 76, no. 2, pp. 440–452, 2016.eng
dcterms.referencesA. Rodina, T. Wang, P. Yan et al., “The epichaperome is an integrated chaperome network that facilitates tumour survival,” Nature, vol. 538, no. 7625, pp. 397–401, 2016.eng
dcterms.referencesX. Lu, L. Xiao, L. Wang, and D. M. Ruden, “Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies ofHsp90 inhibitors and other anti-cancer drugs,” Biochemical Pharmacology, vol. 83, no. 8, pp. 995–1004, 2012.eng
dcterms.referencesM. Klimczak, P. Biecek, A. Zylicz, and M. Zylicz, “Heat shock proteins create a signature to predict the clinical outcome in breast cancer,” Scientific Reports, vol. 9, no. 1, pp. 7507–7515, 2019.eng
dcterms.referencesC. H. Lai, K. S. Park, D. H. Lee et al., “HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer,” Oncogene, vol. 33, no. 40, pp. 4867–4876, 2014.eng
dcterms.referencesJ. Díaz-Chávez, M. A. Fonseca-Sánchez, E. Arechaga- Ocampo et al., “Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy,” PLoS One, vol. 8, no. 5, p. e64378, 2013.eng
dcterms.referencesL. Liu, C. Fu, M. Yan et al., “Resveratrol modulates intestinal morphology and HSP70/90, NF-κB and EGF expression in the jejunal mucosa of black-boned chickens on exposure to circular heat stress,” Food & Function, vol. 7, no. 3, pp. 1329–1338, 2016.eng
dcterms.referencesK. Sahin, C. Orhan, F. Akdemir, M. Tuzcu, C. Iben, and N. Sahin, “Resveratrol protects quail hepatocytes against heat stress: modulation of the Nrf2 transcription factor and heat shock proteins,” Journal of Animal Physiology and Animal Nutrition, vol. 96, no. 1, pp. 66–74, 2012.eng
oaire.versioninfo:eu-repo/semantics/publishedVersionspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Cellular Mechanisms Triggered by the Cotreatment of Resveratrol and Doxorubicin in Breast Cancer A translational in vitro-in silico model.pdf
Tamaño:
9.26 MB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca